The most popular stories of the week on AJMC®.
Is Targeted Treatment in the Future for Triple-Negative Breast Cancer?
The journal Oncogene recently published results of an investigation into the drivers behind triple-negative breast cancer. Because the disease has such high recurrence and low survival rates, investigators from Manchester, Glasgow, and Sheffield universities sought to better understand what triggers, and arrests, the growth of this subtype of breast cancer.
Stem Cells Prove Effective in Treating MS Neural Damage
Several clinical trials have found mesenchymal stem cell therapy effective in treating neural damage in patients with multiple sclerosis (MS), according to a review published in Stem Cell Investigation.
Youth Newly Diagnosed With HIV Have Advanced Infection, Higher Viral Loads
Close to 80% of HIV-positive individuals are shown to be virally suppressed through their most recent test results, according to data from 2016 through 2018, as well as 32% to 63% of adults older than 24 years. Youth with a new HIV diagnosis, however, come in at only 12%.
DC Circuit Panel Rejects Arkansas Medicaid Work Rules
Writing for the panel, Judge David Sentelle said HHS Secretary Alex Azar ignored predictions that thousands of people would lose their healthcare coverage.
Much of MS Cost Burden Falls on Patients' Shoulders
A British study shows nonmedical costs make up a significant portion of the annual expense generated by MS. Most of those nonmedical costs are not covered by insurance.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen